Festival of Genomics & Biodata 2026
)
Where scientists, clinicians, business leaders, tech companies, investors, patient organisations and policymakers come together to learn, network, collaborate, participate, discover and ultimately translate the latest innovations in science and technology into better patient outcomes. The Festival now covers so much more than genomics. It’s now a great spend of time for just about anyone working in life sciences. AI, biodata, diagnostics, drug discovery, medicine, multi-omics, single-cell, spatial, women’s health… and so many more topics are covered.
Oxford Nanopore will be exhibiting at the Festival of Genomics & Biodata 2026. We will also host a presentation on Wednesday 28 January at 12:00 on the main stage.
Speakers, presentation details and registration below. Please register to save your seat.
Please also visit us at Booth #106.
Agenda
12:00 – 12:30 hrs GMT | Agenda (subject to change) | |
|---|---|---|
12:00 - 12:10 hrs | Clinical to Discovery continuum | Tonya McSherry, Oxford Nanopore Technologies |
12:10 - 12:30 hrs | Sequencing of the UK biobank using Oxford Nanopore | Bjarni V. Halldórsson, DeCODE |
Speakers
We report on our progress in sequencing 50,000 samples from the UK biobank with Oxford nanopore technologies sequencing. ONT sequencing of the UK Biobank will lead to the identification of epigenetic and structural variation associated with the >10,000 disease features and traits already captured in UK Biobank, thus enabling the improved characterisation of disease risk mechanisms and the manner in which regulatory variation can affect gene function. Epigenetics research is hampered by the lack of large deeply phenotyped cohorts that can be accessed by researchers around the globe. UKBB is ideally positioned to help drive forward epigenetic research using Oxford Nanopore Sequencing due to its large cohort, consent structure, availability of deeply phenotyped samples as well as enabling access for a broad research community.
We report on our progress in sequencing 50,000 samples from the UK biobank with Oxford nanopore technologies sequencing. ONT sequencing of the UK Biobank will lead to the identification of epigenetic and structural variation associated with the >10,000 disease features and traits already captured in UK Biobank, thus enabling the improved characterisation of disease risk mechanisms and the manner in which regulatory variation can affect gene function. Epigenetics research is hampered by the lack of large deeply phenotyped cohorts that can be accessed by researchers around the globe. UKBB is ideally positioned to help drive forward epigenetic research using Oxford Nanopore Sequencing due to its large cohort, consent structure, availability of deeply phenotyped samples as well as enabling access for a broad research community.
)
Dr. Bjarni Halldórsson, Principal Investigator, DeCODE
